Fenfluramine Reduces [<sup>11</sup>C]Cimbi-36 Binding to the 5-HT<sub>2A</sub> Receptor in the Nonhuman Primate Brain by Yang, Kai-Chun et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the
Nonhuman Primate Brain
Yang, Kai-Chun; Stepanov, Vladimir; Martinsson, Stefan; Ettrup, Anders; Takano, Akihiro;
Knudsen, Gitte M; Halldin, Christer; Farde, Lars; Finnema, Sjoerd J
Published in:
International Journal of Neuropsychopharmacology
DOI:
10.1093/ijnp/pyx051
Publication date:
2017
Document license:
CC BY-NC
Citation for published version (APA):
Yang, K-C., Stepanov, V., Martinsson, S., Ettrup, A., Takano, A., Knudsen, G. M., ... Finnema, S. J. (2017).
Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain.International Journal of Neuropsychopharmacology, 20(9), 683-691. https://doi.org/10.1093/ijnp/pyx051
Download date: 03. Feb. 2020
Received: April 25, 2017; Revised: June 8, 2017; Accepted: June 18, 2017
© The Author 2017. Published by Oxford University Press on behalf of CINP.
International Journal of Neuropsychopharmacology (2017) 20(9): 683–691
doi:10.1093/ijnp/pyx051
Advance Access Publication: June 20, 2017
Regular Research Article
683
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, 
provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
regular research article
Fenfluramine Reduces [11C]Cimbi-36 Binding to the 
5-HT2A Receptor in the Nonhuman Primate Brain
Kai-Chun Yang, MD; Vladimir Stepanov, PhD; Stefan Martinsson, MSc; 
Anders Ettrup, PhD; Akihiro Takano, MD, PhD; Gitte M. Knudsen, MD, DMSc; 
Christer Halldin, PhD; Lars Farde, MD, PhD; Sjoerd J. Finnema, PhD
Karolinska Institutet and Stockholm County Council, Department of Clinical Neuroscience, Center for 
Psychiatric Research, Stockholm, Sweden (Drs Yang and Stepanov, Mr Martinsson, and Drs Takano, Halldin, 
Farde, and Finnema); Rigshospitalet, Center for Integrated Molecular Brain Imaging, Copenhagen, Denmark 
and University of Copenhagen, Faculty of Health and Medicine Sciences, Copenhagen, Denmark (Drs Ettrup 
and Knudsen); AstraZeneca, PET Science Center at Karolinska Institutet, Personalized Health Care and 
Biomarkers, Stockholm, Sweden (Dr Farde).
Present address (S.J.F.): Yale University, Department of Radiology and Biomedical Imaging, New Haven, CT.
Correspondence: Kai-Chun Yang, MD, Karolinska Institutet and Stockholm County Council, Department of Clinical Neuroscience, Center for Psychiatric 
Research, Karolinska University Hospital, Building R5:02, SE-171 76 Stockholm, Sweden (kai-chun.yang@ki.se).
Abstract
Background: [11C]Cimbi-36 is a serotonin 2A receptor agonist positron emission tomography radioligand that has recently been 
examined in humans. The binding of agonist radioligand is expected to be more sensitive to endogenous neurotransmitter 
concentrations than antagonist radioligands. In the current study, we compared the effect of serotonin releaser fenfluramine 
on the binding of [11C]Cimbi-36, [11C]MDL 100907 (a serotonin 2A receptor antagonist radioligand), and [11C]AZ10419369 
(a serotonin 1B receptor partial agonist radioligand with established serotonin sensitivity) in the monkey brain.
Methods: Eighteen positron emission tomography measurements, 6 for each radioligand, were performed in 3 rhesus monkeys 
before or after administration of 5.0  mg/kg fenfluramine. Binding potential values were determined with the simplified 
reference tissue model using cerebellum as the reference region.
Results: Fenfluramine significantly decreased [11C]Cimbi-36 (26–62%) and [11C]AZ10419369 (35–58%) binding potential values in 
most regions (P < 0.05). Fenfluramine-induced decreases in [11C]MDL 100907 binding potential were 8% to 30% and statistically 
significant in 3 regions. Decreases in [11C]Cimbi-36 binding potential were larger than for [11C]AZ10419369 in neocortical and 
limbic regions (~35%) but smaller in striatum and thalamus (~40%). Decreases in [11C]Cimbi-36 binding potential were 0.9 to 
2.8 times larger than for [11C]MDL 100907, and the fraction of serotonin 2A receptor in the high-affinity state was estimated 
as 54% in the neocortex.
Conclusions: The serotonin sensitivity of serotonin 2A receptor agonist radioligand [11C]Cimbi-36 was higher than for antagonist 
radioligand [11C]MDL 100907. The serotonin sensitivity of [11C]Cimbi-36 was similar to [11C]AZ10419369, which is one of the most 
sensitive radioligands. [11C]Cimbi-36 is a promising radioligand to examine serotonin release in the primate brain.
Keywords: [11C]Cimbi-36, [11C]AZ10419369, [11C]MDL 100907, fenfluramine, serotonin
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Introduction
The serotonin (5-HT) neurotransmission system has an impor-
tant role in the regulation of basic physiological functions as 
well as in higher brain functions such as emotion and cogni-
tion (Cools et al., 2011; Chou et al., 2012). It is of great interest to 
develop noninvasive methods to examine the serotonin system 
in the living primate brain, since a role of this system is impli-
cated in the pathophysiology and treatment of major psychi-
atric disorders. By consequence, several radioligands have long 
since been developed for positron emission tomography (PET) 
imaging of serotonin receptor subtypes and the serotonin trans-
porter (Saulin et al., 2012; Paterson et al., 2013). More recently, 
it has been of particular interest to develop radioligands that 
are sensitive to changes in the endogenous neurotransmitter 
concentration (Laruelle, 2000; Finnema et  al., 2015). This PET 
imaging paradigm is typically interpreted according to the com-
petition model, which postulates that binding of radioligand to 
neuroreceptor will decrease after increases in neurotransmitter 
concentration, and vice versa. For that purpose, there is need for 
radioligands that are sensitive to the endogenous 5-HT concen-
tration in brain.
Some PET radioligands for the 5-HT1A receptor and the 5-HT1B 
receptor such as [11C]CUMI-101, [11C]AZ10419369, and [11C]P943 
have indeed been reported to be sensitive to drug-induced 
changes in the 5-HT concentration (Finnema et  al., 2015). We 
have previously demonstrated that [11C]AZ10419369, a 5-HT1B 
receptor partial agonist radioligand, is sensitive to increases 
in serotonin concentration, as fenfluramine reduced [11C]
AZ10419369 binding up to 50% in the monkey brain (Finnema 
et al., 2010b, 2012). Furthermore, [11C]AZ10419369 allowed detec-
tion of the relatively low changes in 5-HT concentration in the 
human brain induced by escitalopram, a selective serotonin 
reuptake inhibitor (Nord et al., 2013). As modulation of multiple 
target proteins is one of the current strategies in the develop-
ment of novel psychotropic drugs (Bang-Andersen et al., 2011; 
Varnäs et  al., 2016), it is important to develop 5-HT-sensitive 
PET radioligands targeting 5-HT receptor subtypes other than 
5-HT1A and 5-HT1B. It has been suggested that the 5-HT2A recep-
tor could be a promising target for that purpose (Paterson et al., 
2010; Tyacke and Nutt, 2015). However, in initial PET studies in 
the primate brain using 5-HT2A receptor antagonist radioligands 
such as [11C]MDL100907, no or limited 5-HT sensitivity has been 
reported (Paterson et al., 2010; Quednow et al., 2012; Talbot et al., 
2012; Finnema et al., 2015).
The binding of agonist radioligands has been proposed to be 
more sensitive to alterations in neurotransmitter concentration 
than the binding of antagonist radioligands at the same target 
protein (Paterson et al., 2010; Finnema et al., 2015). This hypoth-
esis has been based on the ternary complex model that suggests 
that receptors can be in 2 functional states (De Lean et al., 1980; 
Finnema et  al., 2010a). Whereas agonists have high affinity to 
the functional G-protein coupled receptor and low affinity to the 
G-protein uncoupled receptor, antagonists have similar affin-
ity to both states of the receptor. Therefore, neurotransmitters 
(being endogenous agonists) may more markedly compete with 
radioligand binding to the high-affinity state receptor than to 
the low-affinity state receptor. This hypothesis has been sup-
ported by the higher dopamine sensitivity of dopamine D2/D3 
receptor agonist radioligands than antagonists (Narendran 
et al., 2004, 2010; Seneca et al., 2006; Shotbolt et al., 2012; Gallezot 
et  al., 2014). Considering the low fraction (13%-45%) of 5-HT2A 
receptors in the high-affinity state in vitro (Sleight et al., 1996; 
Fitzgerald et al., 1999; Gray et al., 2003; Hazelwood and Sanders-
Bush, 2004), there may be prominent differences in 5-HT sen-
sitivity between agonist and antagonist radioligands for this 
receptor subtype.
[11C]Cimbi-36 is the first 5-HT2A receptor agonist radioligand 
(Ettrup et al., 2011) that has been characterized both in nonhu-
man primates (NHPs) (Finnema et al., 2014) and humans (Ettrup 
et al., 2014). The 5-HT sensitivity of [11C]Cimbi-36 has recently 
been evaluated in the pig brain (Jørgensen et al., 2016), confirm-
ing that [11C]Cimbi-36 binding was sensitive to the 4- to 11-fold 
increases in 5-HT concentration demonstrated by microdialysis. 
Therefore, [11C]Cimbi-36 might be a promising radioligand for 
measurement of increases in 5-HT concentration in the living 
primate brain.
The aim of this study was to evaluate the 5-HT sensitivity 
of [11C]Cimbi-36 in the NHP brain. Using a within-subject com-
parison study design, the sensitivity was directly compared with 
that of [11C]AZ10419369 binding to the 5-HT1B receptor, a refer-
ence radioligand with established serotonin sensitivity, and that 
of the 5-HT2A receptor antagonist radioligand [
11C]MDL 100907 
(Ito et  al., 1998). Fenfluramine was the drug administered to 
induce 5-HT release (Rothman and Baumann, 2002). The study 
design also allowed for an estimation of the fraction 5-HT2A 
receptors in the high affinity state (Narendran et al., 2004). We 
hypothesized that the 5-HT sensitivity of [11C]Cimbi-36 would 
be higher than for [11C]MDL 100907 and different from [11C]
AZ10419369 due to differences in the affinity of 5-HT to the tar-
get receptors (Paterson et al., 2010).
Methods
Subjects
The NHP study was approved by the Animal Research Ethical 
Committee of the Northern Stockholm region (Dnr N386/09 and 
N452/11). Three female rhesus monkeys (Macaca mulatta) with a 
mean body weight of 7.9 kg (range: 5.2–13.5 kg) were included. 
Significance Statement
The serotonin (5-HT) neurotransmission system is important for regulating brain functions. Positron emission tomography (PET) 
imaging could be applied to examine changes in endogenous 5-HT concentration in the living brain if adequate radioligands 
are available. Agonist radioligands have been suggested to be more sensitive to changes in neurotransmitter concentration than 
antagonist radioligands to the same target. In the current within-subject comparison study, we demonstrated that the 5-HT2A 
receptor agonist radioligand [11C]Cimbi-36 was sensitive to fenfluramine-induced 5-HT release in the nonhuman primate brain. 
The 5-HT sensitivity of [11C]Cimbi-36 was higher than that of [11C]MDL100907, a 5-HT2A receptor antagonist radioligand, and com-
parable with that of [11C]AZ10419369, a 5-HT1B receptor radioligand and one of the most 5-HT sensitive radioligands. Our results 
support that [11C]Cimbi-36 is a promising radioligand to detect increases in 5-HT concentration in the primate brain.
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The caring and experimental procedures were performed 
according to the Guidelines for planning, conducting and docu-
menting experimental research (Dnr 4820/06-600) of Karolinska 
Institutet and the Guide for the Care and Use of Laboratory 
Animals: Eighth Edition (Council, 2011).
Preparation of Radioligands
[11C]Cimbi-36, [11C]MDL 100907, and [11C]AZ10419369 were pre-
pared according to procedures reported previously (Lundkvist 
et  al., 1996; Pierson et  al., 2008; Andersson et  al., 2011; Ettrup 
et al., 2011).
Study Design
A total of 18 PET measurements (6 for each radioligand) were 
performed on 9 experimental days. On each experimental day, a 
baseline PET measurement was performed in the morning and 
repeated after pretreatment with fenfluramine 5  mg/kg. The 
2 PET measurements were performed approximately 3 hours 
apart. The fenfluramine dose was selected to achieve a substan-
tial increase in 5-HT concentration and has been demonstrated 
to induce a 20-fold increase in a microdialysis study in monkeys 
(Udo de Haes et al., 2006). Racemic fenfluramine was formulated 
in saline and was i.v. infused (1 mL/kg) over 10 minutes, starting 
30 minutes before injection of radioligand.
PET Experimental Procedures
Anesthesia was initiated by intramuscular injection of keta-
mine (~10 mg/kg) and, after tracheal intubation maintained by 
a mixture of sevoflurane (2%-8%), oxygen, and medical air. PET 
measurements were conducted in High Resolution Research 
Tomograph. A 6-minute transmission scan (using a single 137Cs 
source) was followed by acquisition of list-mode data for 123 
minutes after i.v. bolus injection of radioligand. During the PET 
measurements after fenfluramine pretreatment, 7 venous blood 
samples (at -40, -5, 15, 30, 60, 90, and 120 minutes after injection 
of radioligand) were collected for determination of the fenflu-
ramine concentration in plasma.
Determination of Plasma Fenfluramine and 
Norfenfluramine Concentrations
The main metabolite of fenfluramine, norfenfluramine, is also a 
potent 5-HT releaser (Rothman and Baumann, 2002). Therefore, 
the plasma concentrations of both fenfluramine and norfenflu-
ramine were determined using liquid chromatography-mass 
spectrometry as described in supplementary Materials and 
Methods.
Magnetic Resonance Imaging (MRI)
T1-weighted MRI images were acquired for each monkey on 
a GE 1.5 Tesla Signa MRI scanner using a 3D spoiled gradient 
recalled protocol with repetition time 21 milliseconds, flip angle 
35°, FOV 12.8, matrix 256 × 256 × 128, and 128 × 1.0 mm2 slices.
Image Data Analysis and Quantification
The MRI images were reoriented to the anterior-posterior com-
missure plane, and non-brain tissues were removed manually 
using the Image Processing and VOI Analysis Tool (PBAS) in 
PMOD (version 3.704; PMOD Technologies). The processed brain 
MRI images were then corrected for inhomogeneous intensity 
by applying the N4 algorithm (Tustison et  al., 2010) using the 
Advanced Normalization Tools software package (http://stnava.
github.io/ANTs/). PET images were preprocessed according to 
previously reported methods (Varrone et al., 2009) with recon-
structed image frames binned as: 9 × 10 seconds, 2 × 15 seconds, 
3 × 20 seconds, 4 × 30 seconds, 4 × 60 seconds, 4 × 180 seconds, 
and 17 × 360 seconds.
For each of the 9 baseline measurements, a summed PET 
image was generated for PET-MRI co-registration. Time frames 
for the summed PET image were based on high tissue counts 
and optimal tissue contrast to enable PET-MRI co-registration. 
The applied time frames were 12 to 63 minutes for [11C]Cimbi-
36, 21 to 75 minutes for [11C]MDL 100907, and 5 to 18 minutes for 
[11C]AZ10419369. Each summation image was co-registered to its 
individual MRI brain image by the Rigid matching algorithm with 
default settings for primate in the PMOD Fuse It Tool (PFUSEIT). 
The resulting transformation matrices were applied to the 2 PET 
data sets obtained for each monkey on the same day.
Fourteen volumes of interest (VOIs) were defined based on 
the NeuroMaps atlas in the INIA19 rhesus template (Rohlfing 
et  al., 2012), including 3 striatal regions: putamen, caudate 
nucleus (CN), and ventral striatum (VS); 4 neocortical regions: 
frontal cortex (FC), parietal cortex (PC), temporal cortex (TC), and 
occipital cortex (OC); 3 limbic regions: anterior cingulated cortex 
(ACC), amygdala, and hippocampus; and finally, VOIs for thala-
mus, midbrain, cerebellum, and whole brain. The VOIs were 
selected based on regional 5-HT1B and 5-HT2A receptor distribu-
tion and are similar as in previous PET studies in NHPs using 
[11C]Cimbi-36, [11C]MDL 100907, and [11C]AZ10419369 (Finnema 
et al., 2012, 2014). Each monkey’s brain MRI image was normal-
ized to the INIA19 rhesus template by the Deformable matching 
algorithm with default settings for primate in the PFUSEIT, and 
the resulting normalization matrix was used to inversely trans-
form the template VOIs into the individual MRI space.
Calculation of Binding Potential (BPND) and Change 
after Pretreatment
For each VOI, a decay-corrected time–activity curve was gen-
erated from the co-registrated dynamic PET data. BPND values 
were calculated using the simplified reference tissue model 
(Lammertsma and Hume, 1996), with cerebellum as the refer-
ence region (Meyer et al., 2010; Varnäs et al., 2011; Talbot et al., 
2012; Finnema et  al., 2014). The identifiability of BPND values 
was evaluated by the estimate of SE during the fitting process 
by using the Marquardt-Levenberg algorithm (Marquardt, 1963) 
and expressed as the percentage of SE (%SE), calculated accord-
ing to the following equation: 
 % .SE = ´Standarderror in estimation
estimation
ND
ND
BP
BP
100  (1)
The relative change in BPND values (∆BPND) (%) was calculated 
using the following equation: 
 ∆BP BP BP
BPND
 %
( )
.( ) = - ´ND ND
ND
Pretreatment Baseline
Baseline
100  (2)
Statistical Analysis
Changes in parameters between the 2 PET measurements per-
formed on the same day were assessed by paired t test. All sta-
tistical analyses were performed in GraphPad Prism (version 
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6.05; GraphPad Software). The threshold of significance set as 
P < .05 (1-tailed) for fenfluramine induced decreases in BPND and 
P < .05 (2-tailed) for changes in other parameters.
Results
Radiochemistry
The mean radiochemical purity for each of 3 injected radio-
ligands was 99% (range: 97–100%, n  =  6 for each radioligand). 
Comparing radioligand injection parameters between baseline 
and pretreatment PET measurements for the same radioligand, 
a slightly higher injected radioactivity of [11C]AZ10419369 after 
pretreatment (188 MBq) than baseline (183 MBq) and higher 
injected mass of [11C]MDL 100907 after pretreatment (0.21 μg) 
than baseline (0.17 μg) were observed. Otherwise, there were no 
significant differences (supplementary Table 1).
Plasma Concentrations of Fenfluramine and 
Norfenfluramine
The time courses for the mean plasma concentrations of fenflu-
ramine and norfenfluramine are presented in Figure 1. During 
the PET measurement, the mean plasma concentration val-
ues of fenfluramine and norfenfluramine were similar for the 
9 experimental days. The mean (n = 3) values for fenfluramine 
and norfenfluramine were 2.39 μM and 0.75 μM after [11C]Cimbi-
36, 2.44 μM and 0.86 μM after [11C]MDL 100907, and 2.59 μM and 
0.83 μM after [11C]AZ10419369, respectively.
Fenfluramine-Induced Changes in Radioligand 
Binding
Regional BPND values could be reliably identified (%SE ≤ 10%) for 
most regions (Table 1), although the identifiability was slightly 
weaker for the VS (11.3  ±  2.3%, mean ± SD, n  =  6), amygdala 
(10.5 ± 3.5%), and MB (16.5 ± 9.5%) in the [11C]Cimbi-36 experi-
ments. Following administration of fenfluramine, radioactivity 
concentration in a majority of examined VOIs was reduced when 
compared with baseline (Figure 2). The reduction in [11C]Cimbi-
36 BPND was statistically significant in 12 of the 13 examined 
brain regions (except putamen). For [11C]AZ10419369, BPND was 
also significantly reduced in all 13 brain regions. In contrast, the 
regional reduction in [11C]MDL 100907 BPND was not significant 
in most regions except for 3 (TC, ACC, and thalamus) (Table 1; 
Figure 3). For the whole brain, the mean reductions in BPND for 
[11C]MDL 100907, [11C]Cimbi-36, and [11C]AZ10419369 were 25.8%, 
49.4%, and 46.3%, respectively.
Fenfluramine-induced [11C]Cimbi-36  ∆BPND was larger than 
[11C]MDL 100907 ∆BPND (Table 1). There were regional differences 
in fenfluramine-induced ∆BPND between [
11C]Cimbi-36 and [11C]
AZ10419369 as the decreases in [11C]Cimbi-36 BPND were larger 
than for [11C]AZ10419369 in neocortical and limbic regions 
(~35%), but smaller in striatum and thalamus (~40%) (Table 1).
Discussion
The aim of the present study in NHPs was to examine the sen-
sitivity of the 5-HT2A receptor agonist radioligand [
11C]Cimbi-36 
for changes in the endogenous serotonin concentration. A main 
observation was that the binding of [11C]Cimbi-36 was sensitive 
to 5-HT release induced by fenfluramine. The results are con-
sistent with a recent PET study in pigs in which fenfluramine 
reduced the BPND values by 44% (Jørgensen et al., 2016). Moreover, 
the agonist radioligand [11C]Cimbi-36 was more sensitive to 
5-HT release than the antagonist 5-HT2A receptor radioligand 
[11C]MDL100907. In addition, the 5-HT sensitivity of [11C]Cimbi-
36 binding was comparable with that for [11C]AZ10419369 bind-
ing to the 5-HT1B receptor. In summary, [
11C]Cimbi-36 appears to 
be one of the most sensitive radioligands so far developed for 
detection of changes in the endogenous 5-HT concentration in 
the primate brain.
The larger fenfluramine-induced change in ∆BPND for [
11C]
Cimbi-36 than for [11C]MDL 100907 is in line with the previously 
reported higher dopamine sensitivity of dopamine D2/D3 recep-
tor agonist radioligands than antagonist radioligands such as 
[11C]raclopride (Narendran et al., 2004, 2010; Seneca et al., 2006; 
Shotbolt et al., 2012; Gallezot et al., 2014). The 92% to 278% larger 
regional fenfluramine-induced effect on [11C]Cimbi-36 binding 
than on [11C]MDL 100907 binding in the neocortex is compara-
ble with the 42% to 153% larger regional amphetamine-induced 
decreases in radioligand binding using different dopamine D2/
D3 receptor agonist radioligands in comparison with [
11C]raclo-
pride. The results are thus consistent with the view that agonist 
radioligands are more sensitive to changes in neurotransmitter 
concentrations than antagonists.
It is worth noting that, in contrast to [11C]MDL 100907 (Pehek 
et al., 2006), [11C]Cimbi-36 has a relatively poor selectivity for the 
5-HT2A receptor subtype. The affinity (Ki) is 0.5 to 0.8 nM for the 
5-HT2A receptor, 0.5 nM for the 5-HT2B receptor, and 1.7 nM for 
the 5-HT2C receptor (Ettrup et al., 2011). We previously reported 
that in the monkey brain, the relative binding of [11C]Cimbi-36 
to [11C]MDL 100907 in several regions, including amygdala, hip-
pocampus, thalamus, and midbrain, is higher than in neocorti-
cal regions. These differences are most likely attributable to the 
binding of [11C]Cimbi-36 to 5-HT2C receptors located either in 
these regions or in the adjacent choroid plexus (Finnema et al., 
2014). Interestingly, similar patterns were also observed in the 
human brain (Ettrup et al., 2016). Nonetheless, the relative effect 
of fenfluramine, measured as the ratio of [11C]Cimbi-36 ∆BPND to 
Figure 1. Time-course for mean plasma concentration of (a) fenfluramine (FEN) and (b) norfenfluramine during positron emission tomography (PET) experiments fol-
lowing injection of [11C]Cimbi-36, [11C]MDL 100907, or [11C]AZ10419369 (n = 3 for each radioligand). The capped horizontal lines represent the period of PET measurement.
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Table 1. Effect of Fenfluramine (FEN) on Regional Binding Potential (BPND) Values (n = 3)
Region
[11C]MDL 100907 [11C]Cimbi-36 [11C]AZ10419369
Baseline FEN ∆BPND (%) Baseline FEN ∆BPND (%) Baseline FEN ∆BPND (%)
Put 1.05 0.94 -10.3 0.69 0.61 -11.4 0.78 0.44 -46.5*
CN 1.15 0.93 -17.4 0.86 0.53 -38.0* 0.65 0.37^ -46.1*
VS 1.16 0.91 -21.4 0.80^ 0.56^ -30.4* 1.36 0.66^ -51.9**
FC 3.53 2.39 -29.9 1.73 0.83 -51.3* 0.78 0.51 -35.2*
PC 2.95 1.98 -30.0 1.44 0.68 -51.8* 0.67 0.40 -42.6*
TC 2.95 2.05 -28.9* 1.79 0.80 -54.6* 0.72 0.42 -42.3*
OC 2.47 1.73 -26.1 1.17 0.45 -62.2** 1.17 0.51 -58.2*
ACC 3.46 2.41 -29.3* 2.14 1.03 -51.1* 0.91 0.59 -37.0*
Amyg 1.02 0.76 -25.2 0.86 0.54^ -36.6* 1.05 0.55 -47.6*
HC 1.27 0.85 -29.8 1.03 0.49 -51.5** 0.63 0.37^ -41.3*
Thal 0.78 0.72 -8.2* 0.70 0.52 -25.8** 0.94 0.49 -48.1*
MB 0.84^ 0.67 -16.3 0.66^^ 0.37^^ -43.3** 0.92 0.50^ -46.3*
WB 2.03 1.46 -25.8 1.19 0.60 -49.4** 0.69 0.38 -46.3*
Abbreviations: ACC, anterior cingulated cortex; Amyg, amygdala; ∆BPND (%), 
( )BP BP
BP
ND ND
ND
Pretreatment Baseline
Baseline
− ´100; CN, caudate nucleus; FC, frontal cortex; HC, hip-
pocampus; MB, midbrain; OC, occipital cortex; PC, parietal cortex; Put, putamen; TC, temporal cortex, Thal, Thalamus; VS, Ventral striatum; WB, whole brain.
Data presented as mean (n = 3).
Identifiability (%SE) =  .Standard error of estimation
estimation
ND
ND
BP
BP
´100
^15% ≥ mean identifiability (%SE) > 10%, ^^20% ≥ mean %SE > 15%.
*P < .05, **P < .01 (1-tailed) by paired t test.
Figure 2. Magnetic resonance images (MRI) and corresponding coregistrated positron emission tomography (PET) summation images (average of frames from 9 to 
123 min) of [11C]MDL 100907, [11C]Cimbi-36, and [11C]AZ10419369 during baseline and post-fenfluramine (FEN) conditions in NHP3. (a) Axial view of images at the level of 
caudate nucleus. (b) Axial view of images at the level of amygdala/hippocampus; note the difference in the range of the standardized uptake values (SUVs) color bars 
for the different radioligands. SUVs were calculated from the radioactivity concentration as [kBq/cm3] / (radioactivity injected [MBq] / body weight [kg]). ACC, anterior 
cingulate cortex; Amyg, amygdala; CN, caudate nucleus; FC, frontal cortex; HC, hippocampus; PC, parietal cortex; OC, occipital cortex; TC, temporal cortex.
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[11C]MDL 100907 ∆BPND, was in these 4 regions similar to the ratio 
in neocortical regions where [11C]Cimbi-36 binds selectively to 
the 5-HT2A receptors (Finnema et al., 2014). These observations 
for the neocortical regions suggest that there is a limited contri-
bution of 5-HT2C receptor binding to the higher 5-HT sensitivity 
of [11C]Cimbi-36 when compared with [11C]MDL 100907.
The concept of G-protein coupled receptors being in high- 
and low-affinity states was originally based on studies in vitro 
(De Lean et al., 1980; Finnema et al., 2010a). In the present study, 
the fraction of 5-HT2A receptors in the high-affinity state in vivo 
was estimated by dividing the [11C]MDL 100907 ∆BPND by the [
11C]
Cimbi-36  ∆BPND (supplementary Methods). This approach was 
previously applied to dopamine D2/D3 receptor agonist radioli-
gands and [11C]raclopride (Narendran et al., 2004, 2010; Seneca 
et al., 2006; Shotbolt et al., 2012). For reliable estimation of the 
fraction in vivo, we recommend using neocortical regions, where 
[11C]Cimbi-36 binding is specific to 5-HT2A receptors (Finnema 
et  al., 2014) and where the test-retest variability is favorable 
for both radioligands (Talbot et al., 2012; Ettrup et al., 2016).The 
fraction of 5-HT2A receptors in the high-affinity state (54%) was 
slightly higher than previously reported values from in vitro 
binding assays (13%-45%) (Sleight et al., 1996; Fitzgerald et al., 
1999; Gray et al., 2003; Hazelwood and Sanders-Bush, 2004). The 
present in vivo estimates should be taken with caution, since 
they were based on data obtained in only 3 NHPs but may sup-
port the view that high- and low-affinity states are valid con-
cepts also in vivo.
 [11C]AZ10419369 is one of the most sensitive radioligands for 
endogenous 5-HT (Paterson et al., 2010; Finnema et al., 2015). In 
addition to high reduction (~50%) in [11C]AZ10419369 binding to 
Figure 3. Individual binding potential (BPND) values before and after pretreatment with fenfluramine (FEN) 5.0 mg/kg in 12 predefined volumes of interest: putamen 
(Put), caudate nucleus (CN), ventral striatum (VS), frontal cortex (FC), parietal cortex (PC), temporal cortex (TC), occipital cortex (OC), anterior cingulate cortex (ACC), 
amygdala (Amyg), hippocampus (HC), thalamus (Thal), midbrain (MB), and whole brain (WB). (a) [11C]MDL 100907, (b) [11C]Cimbi-36, and (c) [11C]AZ10419369.
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the 5-HT1B receptor after administration of fenfluramine 5 mg/
kg, the binding was also demonstrated to be sensitive to smaller 
changes in 5-HT concentration such as after administration of 
selective serotonin reuptake inhibitors (Finnema et  al., 2010b, 
2012; Nord et  al., 2013). The present study demonstrates that 
the 5-HT sensitivity of [11C]Cimbi-36 binding is similar to that 
of [11C]AZ10419369. However, due to the relatively high expres-
sion of 5-HT2A receptors in neocortical and limbic regions 
(Paterson et al., 2010), [11C]Cimbi-36 may be advantageous to [11C]
AZ10419369 for examination of pathophysiology and treatment 
effects on serotonergic neurotransmission in those regions.
A limitation of the present study is that fenfluramine and 
norfenfluramine have been reported to bind to 5-HT2 receptors 
and the potential contribution of direct occupancy, resulting in 
a decrease in radioligand binding, should therefore be carefully 
considered (Tyacke and Nutt, 2015). In the present study, the 
plasma concentrations of fenfluramine and norfenfluramine 
were measured to estimate the direct occupancy effects (sup-
plementary Methods). The estimated occupancy levels (sup-
plementary Table 2) for the 5-HT2A receptor, the 5-HT2C receptor, 
and the 5-HT1B receptor (5–13%) were much lower than the 
observed reductions in radioligand binding (35%-62%). Although 
the 5-HT2B receptor occupancy was estimated to be relatively 
high (50%), the low and restricted expression of 5-HT2B recep-
tors in brain (Nichols and Nichols, 2008) suggests that this bind-
ing would have negligible effect on [11C]Cimbi-36 binding in 
the regions examined. In conclusion, a major proportion of the 
∆BPND induced by fenfluramine administration can be attributed 
to 5-HT release and is not likely to represent drug occupancy at 
the target receptor.
Another potential limitation of the current PET study is 
the use of anesthesia. Ketamine and isoflurane have previ-
ously been shown not to affect 5-HT2A receptor binding of [
18F]
altanserin in the rodent brain (Elfving et al., 2003). Anesthetic 
doses of ketamine have however been reported to increase 
[11C]AZ10419369 binding in NHP brain, but had no effect on 
fenfluramine-induced decreases in [11C]AZ10419369 binding 
(Yamanaka et  al., 2014). Interestingly, ketamine/xylazine and 
isoflurane have been reported to elevate the dopamine sensitiv-
ity of dopamine D2/D3 receptor agonist radioligands in NHPs and 
rats, respectively, while isoflurane did not affect [3H]raclopride 
binding (Ohba et al., 2009; McCormick et al., 2011). However, the 
increased dopamine sensitivity of dopamine D2/D3 receptor ago-
nist vs antagonist radioligands was confirmed in awake human 
studies (Narendran et  al., 2010; Shotbolt et  al., 2012). Future 
studies to compare the 5-HT sensitivity of [11C]Cimbi-36 and [11C]
MDL 100907 in awake humans are warranted to exclude poten-
tial anesthesia effects.
The present results may also serve as a starting point for 
translation to humans, as the NHP brain has higher similarity 
to the human brain than the pig brain (Capitanio and Emborg, 
2008). In one previous study, dexfenfluramine (40 or 60 mg p.o.) 
was shown to reduce [18F]altanserin antagonist binding to the 
5-HT2A receptor in human volunteers (Quednow et  al., 2012). 
Following safety considerations, the proposed maximal dose 
of dexfenfluramine suitable for human use was 1  mg/kg p.o. 
(Quednow et  al., 2012), which is lower than the 5  mg/kg used 
in the present study. Therefore, it might be interesting to evalu-
ate the effect of a lower dose of fenfluramine (1 mg/kg) on [11C]
Cimbi-36 binding in NHPs in comparison with current results. 
Nonetheless, since 5 mg/kg reduced [11C]Cimbi-36 by 55%, it may 
be anticipated that [11C]Cimbi-36 binding may be sensitive to 
5-HT release induced also by dexfenfluramine 1 mg/kg in future 
human studies.
In conclusion, our results support that [11C]Cimbi-36 is a 
promising radioligand to detect increases in 5-HT concentra-
tion in the primate brain. The 5-HT sensitivity of [11C]Cimbi-36 is 
higher than for [11C]MDL 100907 but similar to [11C]AZ10419369. 
Future studies are warranted to evaluate the sensitivity of [11C]
Cimbi-36 binding to smaller increases in 5-HT concentration 
and to replicate the current observations in the human brain.
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